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REDUCTION OF URGENCY SEVERITY IS THE MOST IMPORTANT FACTOR
IN THE SUBJECTIVE THERAPEUTIC OUTCOME OF INTRAVESICAL
ONABOTULINUMTOXINA INJECTION FOR OVERACTIVE BLADDER
Jia-Fong Jhang, Hann-Chorng Kuo. Department of Urology, Buddhist Tzu Chi
General Hospital and Tzu Chi University, Hualien, Taiwan
Purpose: This study investigated the relationship between the subjective
outcome assessment and objective parameters after intravesical onabo-
tulinumtoxinA injection in patients with overactive bladder.
Materials and Methods: A total of 77 patients with urodynamically
conﬁrmed detrusor overactivity were treated with intravesical injection of
100 U of onabotulinumtoxinA in 20 divided injections (5 U in 0.5 ml
normal saline each) at different sites sparing the trigone. The primary end-
point was the change in the Global Response Assessment (GRA) 3 months
after treatment. All patients were monitored monthly after treatment for
up to 6 months. Patients were divided into the successful and failed
treatment groups according to the change in their GRA ( 2 and  1,
respectively) 3 months after injection. The changes in voiding diary vari-
ables, Urgency Severity Score (USS), Overactive Bladder Symptom Score
(OABSS), maximal bladder capacity (MBC), post-void residual (PVR) vol-
ume, and voiding efﬁciency (VE) were compared between groups at each
time point
Results: Overall, the USS and OABSS and MBC improved after treatment.
Three months after BoNT-A injection, 49 (64%) patients reported an
improvement in the GRA of 2 (n¼ 30) or 3 (n¼ 19). Six months after
treatment only USS, OABSS, and urgency episodes showed signiﬁcant
difference between the groups. No signiﬁcant difference in MBC, PVR or VE
was noted between groups at 6 months.
Conclusion: Subjective, successful treatment outcomes of intravesical
onabotulinumtoxinA injection for treatment of overactive bladder were
signiﬁcantly associatedwith a reduction in USS and decreased urgency and
urge urinary incontinence episodes.
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SAFETY AND EFFICACY OF BOTULINUM TOXIN A TREATMENT FOR
PATIENTS WITH DETRUSOR OVERACTIVITY AND INADEQUATE
CONTRACTILITY
Shu-Yu Wu, Hann-Chorng Kuo. Department of Urology, Buddhist Tzu Chi
General Hospital and Tzu Chi University Hualien, Taiwan
Purpose: Overactive bladder (OAB) is common in older adults and is
associated with substantial impairment in mental health and quality of
life. Part of the patients with underactive bladder (UAB) or detrusor un-
deractivity (DU) may have both detrusor hyperactivity and inadequate
contractility (DHIC), resulting in UUI and large PVR. Botulinum toxin A
(BoNT-A) signiﬁcantly improves OAB symptoms and urodynamic param-
eters in OAB. However, the increased PVR volume and risk of urinary tract
infection (UTI) may show after BoNT-A treatment.
Materials and Methods: This study retrospectively analyzed the thera-
peutic efﬁcacy and safety in OAB patients who had a baseline PVR >100ml
or VE <67% and received intravesical BoNT-A 100U injections A total of 21
patients with urodynamically proven DHIC and 21 age-matched
controlled OAB patients with urodynamic DO were selected from our
previous clinical trials. Patients of either gender, aged 20 years, with
urodynamic DO and at least one episode of urgency (urgency severity
scale [USS] score 2) or urgent urinary incontinence (UUI) per day, as
recorded in a 3-day voiding diary, were enrolled. All patients had been
managed with behavioral modiﬁcation and treated with a certain num-
ber. Patients were treated with suburothelial injections of 100 U BoNT-A,
total 20 injections in the bladder body, sparing the trigone. All patients
were evaluated at baseline, 2 weeks, and 1, 3, and 6 months after treat-
ment. The common AEs included acute urinary retention (AUR) (severe
difﬁculty urinating with a PVR volume >250 mL and necessitating theuse
of an indwelling catheter or CIC), gross hematuria, and general weakness
during the early stage and a large PVR volume >250 mL, straining to void
(experiencing difﬁculty urinating and requiring abdominal straining to
empty the bladder, which was not experienced before treatment), andUTI (symptomatic or asymptomatic with a WBC count > 10/HPF in uri-
nalysis) during the follow-up period.
Results: The mean age of DHIC and OAB patients were 71.2 ± 8.2 and
70.9 ± 14.1 years, respectively. The subjective symptom scores after
BoNT-A, including OABSS, USS, PPBC and GRA all showed signiﬁcantly
improved in both groups and no difference between groups. However,
the changes of urgency episodes per 3 days were only noted in OAB
patients after BoNT-A injection. UUI was signiﬁcantly improved at 3
months and frequency episode was signiﬁcantly improved at 6 months
in OAB patients, but not in DHIC patients. Interestingly, there was no
increase of bladder capacity or voided volume in either group. Qmax
showed no signiﬁcant change after BoNT-A injection in either group.
PVR increased in DHIC patients at 2 and 4 weeks, but not at 3 and 6
months after BoNT-A injection. However, in OAB patients, the signiﬁcant
increase of PVR was noted at 2 months and lasted to 6 months. VE also
showed the same changes as that noted in PVR in DHIC and OAB pa-
tients. AUR was noted in 7 and 3 patients, large PVR >250ml in 12 and 7
patients, difﬁcult urination in 15 and 14 patients, and UTI in 8 and 4
patients of DHIC and OAB patients, respectively. After BoNT-A injection,
7 DHIC patients and 16 OAB patients considered the treatment was
effective in improving quality of life. Among these patients, the thera-
peutic efﬁcacy lasted for a mean of 2.3 months and 4.5 months in DHIC
and OAB patients, respectively.
Conclusions: Patients with DHIC might not beneﬁt from intravesicl BoNT-
A injection for their OAB symptoms. The urgency episodes are not
decreased after BoNT-A injection and the therapeutic duration is signiﬁ-
cantly shorter than that of OAB patients.
PD2-6:
FEMALE VOIDING DYSFUNCTION e A VIDEOURODYNAMIC ANALYSIS OF
THE ROLE OF BLADDER NECK AND PELVIC FLOOR MUSCLES
Cheng-Ling Lee, Hann-Chorng Kuo. Department of Urology, Buddhist
Tzu-Chi General Hospital, Hualien, Taiwan
Purpose: To date, there is lack of consensus about a precise diagnosis and
deﬁnition of voiding dysfunction (VD) inwomen. Symptoms of storage and
voiding can manifest solely or co-existing, which might suggest an inde-
pendent pathophysiology or involved with one another. This makes
treatment for female VD especially challenging. In this study, we examined
the underlying pathogenesis of female VD and in particular, focused on the
role of bladder neck and pelvic ﬂoor muscles.
Materials and Methods: We retrospectively reviewed all video-urody-
namic study (VUDS) from 1914 womenwho referred to us for investigation
of VD. Based on their VUDS ﬁndings, female VD can be categorized into 2
domains: bladder dysfunction (BD) and bladder outlet dysfunction (BOD).
BOD is consisted of bladder neck dysfunction (BND), cystolocele,
dysfunctional voiding (DV), poor relaxation of the external sphincter
(PRES), and urethral stricture (US). We analyzed the age distribution,
presence of detrusor overactivity (DO), inﬂuence of co-morbidities and
treatment modalities in BND and PRES groups.
Results: BOD was responsible for 42.3% of all female VD cases and in
comparison to BD, those with BOD were younger in age (p¼ 0.000). The
most common VUDS ﬁndings of BOD were PRES (41.5%), DV (40.1%) and
BND (12.3%). BNDwas prevalent in patients aged >55 years (72%). Formost
of the BND patients, DO was a concurrent feature especially in those older
than 55 years of age (51.6%). Numbers of co-morbid medical conditions
were identiﬁed in women with VD, including hypertension, type2 dia-
betes, coronary artery disease, chronic kidney disease and chronic
obstructive pulmonary disease; none of thesewere signiﬁcantly associated
with BND. Usage of alpha blockers can signiﬁcantly improve maximal ﬂow
rate (Qmax) in patients with BND from 7.6± 4.39 ml/s to 12.06± 4.99 ml/s
(p¼ 0.000). In addition, transurethral incision of bladder neck (TUI-BN)
can also facilitate self voiding in the cases of BND refractory or intolerant to
alpha blockers.
Conclusions: Voiding dysfunction (VD) in women is rather a complex and
poorly-understood disorder. PRES and DU are two most common di-
agnoses in female VD. BND is prevalent in patients older than 55 and is
highly associated with DO. Alpha blockers and TUI-BN are effective in
improving Qmax in BND.
